Vazoket, tablets 600 mg 30 pcs

Pharmacotherapeutic group: venotonic and venoprotective agent.

TATX code: [C05CA03]

Pharmacological properties

Pharmacodynamics

Diosmin has venotonic action (reduces vein distensibility, increases venous tone (dose-dependent effect), reduces venous congestion), improves lymphatic drainage (increases tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), It improves microcirculation (increases capillary resistance (dose-dependent effect), decreases their permeability), reduces leukocyte adhesion to the venous wall and their migration to paravenous tissue, improves oxygen diffusion and perfusion in the skin tissue, has anti-inflammatory effect. It enhances the vasoconstrictor effect of adrenaline, noradrenaline, serotonin, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane. .

Pharmacokinetics

After oral administration, the drug is rapidly absorbed from the gastrointestinal tract and determined in blood plasma after 2 hours. The maximum plasma concentration is reached 5 hours after ingestion. It is evenly distributed and accumulated in all layers of the wall of the hollow veins and subcutaneous veins of the lower limbs, to a lesser extent in the kidneys, liver, lungs and other organs. Selective accumulation of diosmin and/or its metabolites in the venous vessels reaches a maximum by 9 hours after intake and persists for 96 hours. Diosmin is excreted by the kidneys 79%, by the intestine – 11%, with the bile – 2.4%.

Indications

Varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities; exacerbation of hemorrhoids; microcirculation disorders.

Pharmacological effect

Pharmacotherapeutic group: venotonic and venoprotective agent.

ATX Code: [C05CA03]

Pharmacological properties

Pharmacodynamics

Diosmin has a venotonic effect (reduces the distensibility of veins, increases the tone of the veins (dose-dependent effect), reduces venous stagnation), improves lymphatic drainage (increases the tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases the resistance of capillaries (dose-dependent effect), reduces their permeability), reduces adhesion leukocytes to the venous wall and their migration into paravenous tissues, improves oxygen diffusion and perfusion in the skin tissue, and has an anti-inflammatory effect. Strengthens the vasoconstrictor effect of adrenaline, norepinephrine, serotonin, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane. .

Pharmacokinetics

After oral administration, the drug is rapidly absorbed from the gastrointestinal tract and is detected in the blood plasma after 2 hours. The maximum concentration in blood plasma is achieved 5 hours after administration. It is evenly distributed and accumulates in all layers of the wall of the vena cava and saphenous veins of the lower extremities, and to a lesser extent in the kidneys, liver, lungs and other organs. Selective accumulation of diosmin and/or its metabolites in venous vessels reaches a maximum at 9 hours after administration and persists for 96 hours. Diosmin is excreted 79% by the kidneys, 11% by the intestines, and 2.4% by the bile.

Special instructions

Treatment of exacerbation of hemorrhoids is carried out in combination with other drugs; in the absence of a rapid clinical effect, it is necessary to conduct an additional examination and adjust the therapy.

There is evidence of the possible effectiveness of the drug in the treatment of placental insufficiency, for the prevention of bleeding that occurs when using intrauterine devices and during phlebectomy.

Active ingredient

Diosmin

Composition

Active substance:

diosmin 600 mg.

Excipients: povidone, microcrystalline cellulose, corn starch, magnesium stearate.

Pregnancy

So far, in clinical practice there have been no reports of any side effects when using the drug in pregnant women. Experimental studies did not reveal any teratogenic effects on the fetus.

It is not recommended to take the drug during breastfeeding, since there is no data on the penetration of the drug into breast milk.

Contraindications

Hypersensitivity to the components of the drug, children (under 18 years of age).

Side Effects

In rare cases, from the gastrointestinal tract – dyspeptic disorders.

From the central nervous system – headache.

Interaction

Clinically significant effects of interaction with other drugs have not been described.

Overdose

Overdose symptoms are not described.

Storage conditions

Store at a temperature not exceeding 30 °C.

Keep out of the reach of children.

Shelf life

3 years

Do not use after the expiration date stated on the package.

Manufacturer

Fiteau Laboratoire, France